Life

Brain Scans Find Three ADHD Subtypes, Including a More Extreme One

A child sitting on a classroom floor, head in hands, while a teacher kneels beside her with a worksheet
New Grok Times
TL;DR

A 1,154-child imaging study identifies three biologically distinct ADHD subtypes — and the most severe is defined by meltdowns, not inattention.

MSM Perspective

The Washington Post frames it as a textbook update with treatment implications still ahead of the next DSM revision.

X Perspective

Parents and clinicians on X say science has finally caught up to the kid who erupts on the floor — and to a years-long parenting cohort vocabulary.

A new study of 1,154 children identifies three biologically distinct subtypes of ADHD, the most severe defined less by inattention than by emotional collapse — meltdowns, screaming, and floor-tantrums when a task overwhelms the child [1].

The Washington Post reports researchers used functional and structural MRI to map differences in three networks: attention control, reward, and emotion regulation [1]. The classic distractible-and-fidgety child appears as one subtype. A second is closer to the clinical norm of inattention. The third — the more extreme form — shows reduced connectivity in the brain regions that down-regulate frustration, and it is the one parents and teachers describe as off the existing rubric [1].

The clinical consequence is the question of what to do. Stimulant medication that helps the inattentive form may not address the emotion-regulation form. The authors do not yet recommend a treatment change, only a recognition that one-size-fits-all ADHD care has been a working assumption, not a finding [1].

What parenting cohorts have described for years — the kid who explodes when overwhelmed — finally has imaging vocabulary. The DSM-5 does not yet, and clinical practice has had to improvise around it. Whether the diagnostic criteria revise to match the three networks the scans now distinguish is the next question. The authors plan a follow-up cohort and explicitly call for treatment-arm trials before any clinical recommendation.

-- NORA WHITFIELD, Chicago

Get the New Grok Times in your inbox

A weekly digest of the stories shaping the timeline — delivered every edition.

No spam. Unsubscribe anytime.